Search results
Results from the WOW.Com Content Network
The United States federal government is aggressively pursuing criminal and civil cases against pharmaceutical companies and their employees for promoting off-label uses of prescription drugs. [4] Between 2003 and 2008, U.S. federal prosecutors and state attorneys general brought more than a dozen cases against drug manufacturers for off-label ...
Supporters of direct-to-consumer advertising argue that advertisements increase competition which leads to lower prescription drug prices and new development, citing, for instance, that between 1997 and 2001, spending on research and development in the U.S. increased 59% while spending on promoting drugs directly to patients increased 145%.
The drugs were allegedly promoted for uses not approved by the FDA, and therefore the company's marketing caused non-reimbursable prescriptions to be paid by Medicare and Medicaid (Medicare and Medicaid do not reimburse for off-label drug prescriptions). [20] Six whistleblowers shared a $102 million reward under the False Claims Act. [20]
Using my Mutual of Omaha prescription drug plan, the five milliliter generic prescription would have cost $196.99. Instead I paid $60.45 using GoodRx. GoodRx is free and there is no deductible.
For premium support please call: 800-290-4726 more ways to reach us
For premium support please call: 800-290-4726 more ways to reach us
The following is a list of the 20 largest settlements reached between the United States Department of Justice and pharmaceutical companies from 2001 to 2013, ordered by the size of the total settlement. The settlement amount includes both the civil (False Claims Act) settlement and criminal fine.
Total costs—including $51 million for “public relations, grants, sales support and medical education programs,” and $14.3 million for free samples—were budgeted at just $103 million. That included the salaries of all the salespeople and the cost of the drug itself, which was so low that it did not merit its own line item.